Catalent Pharma Solutions LLC has announced it will be investing $75 million in the expansion of its Madison facility. The project will add approximately 60,000 square feet to Catalent’s existing facility, more than doubling the company’s commercial biomanufacturing capacity and creating an expected 145 additional jobs.
“Through our expansion, we are thrilled to partner with the state to bring more high-tech jobs to the highly skilled people of Wisconsin and help make better treatments to positively impact patients around the world,” said Graham Brearley, general manager of Catalent Biologics.
The Wisconsin Economic Development Corporation (WEDC) is supporting the project with up to $1,300,000 in state income tax credits over the next three years, contingent upon the number of jobs created and the amount of capital investment made during that period.
“We are grateful Catalent has decided to continue investing in Wisconsin and create opportunities in Madison,” said Governor Tony Evers. “The numerous high-paying jobs created by this expansion will require an educated workforce to support new roles, which provides another example of how backing education in Wisconsin creates opportunities for businesses to grow and utilize our strong workforce.”
Madison-based Catalent Pharma Solutions is a subsidiary of Catalent Inc., a global provider of advanced delivery technologies and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. Headquartered in Somerset, New Jersey, the company has more than 30 facilities across five continents.
Catalent Pharma Solutions is part of the company’s biologics and specialty drug delivery business segment, specializing in development, manufacturing and analytical services for new biological entities and biosimilars.
